In this case report, we describe a patient with bronchoalveolar carcinoma that experienced severe bronchorrhea and dyspnea after inhalation of N-acetylcysteine. The adverse reactions occurred both after oral and nebulized administration of N-acetylcysteine, resulting in severe dyspnea and the feeling of ‘drowning’. Bronchorrhea has previously been reported as an uncommon but serious complication of bronchoalveolar carcinoma. We strongly suspect the administration of N-acetylcysteine to be implicated, as the complications occurred immediately after administration of this drug. As the patient suffered from hyperhomocysteinemia, we speculate that an additive or synergistic interaction with homocysteine may have been involved as well.
Suddarth SBAcetylcysteine, a new and effective mucolytic agent. Bull Geisinger1963; 15: 65-69.
2.
Tattersall AB , Bridgman KM, and Huitson A.Acetylcysteine (Fabrol) in chronic bronchitis - a study in general practice. J Int Med Res1983; 11(5): 279-284.
3.
Grandjean EM , Berthet P., Ruffmann R., and Leuenberger P.Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials . Clin Ther2000; 22(2): 209-221.
4.
Sheffner ALThe reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetylL-cysteine. Ann N Y Acad Sci1963; 106: 298-310.
5.
Davis SS, Deverell LCRheological factors in mucociliary clearance. The assessment of mucotropic agents using an in vitro model. Mod Probl Paediatr1976; 19: 207-217.
6.
Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, and Proudfoot ATIntravenous N-acetylcystine: The treatment of choice for paracetamol poisoning. Br Med J1979; 2(6198): 1097-1100.
Bristol-Myers Squibb.Mucomyst drug label information FDA. 2001 .
9.
Read WL, Page NC, Tierney RM, Piccirillo JF, and Govindan R.The epidemiology of bronchioloalveolar carcinoma over the past two decades: Analysis of the SEER database. Lung Cancer2004; 45(2): 137-142.
10.
Lopez-Vidriero M., Charman J., Keal E., and Reid L.Bronchorrhoea. Thorax1975; 30(6): 624-630.
11.
Hidaka N., Nagao K.Bronchioloalveolar carcinoma accompanied by severe bronchorrhea. Chest1996; 110(1): 281-282.
12.
Zielonka TM , Lesiński J., Zukowska M., Domagala-Kulawik J., Kaperski L., Przybylowski T., et al. Bronchorrhea in a case of pneumonic type of bronchioloalveolar carcinoma. Pol Arch Med Wewn2004; 112(2): 961-967.
13.
Spiro SG, Lopez-Vidriero M-T., Charman J., Das I., and Reid L.Bronchorrhoea in a case of alveolar cell carcinoma. J Clin Pathol1975; 28(1): 60-65.
14.
Schools GS, Ray ESBronchiolar carcinoma. A case report of bronchoscopic observation of servere bronchorrhea. Dis Chest1961; 39: 643-645.
15.
Homma H., Kira S., Takahashi Y., and Imai H.A case of alveolar cell carcinoma accompanied by fluid and electrolyte depletion through production of voluminous amounts of lung liquids. Am Rev Respir Dis1975; 111(6): 857-862.
16.
Suga T., Sugiyama Y., Fujii T., and Kitamura S.Bronchioloalveolar carcinoma with bronchorrhoea treated with erythromycin . Eur Respir J1994; 7(12): 2249-2251.
17.
Homma S., Kawabata M., Kishi K., Tsuboi E., Narui K., Nakatani T., et al. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma. Chest1999; 115(5): 1465-1468.
18.
Hudson E., Lester JF, Attanoos RL, Linnane SJ, and Byrne A.Successful treatment of bronchorrhea with octreotide in a patient with adenocarcinoma of the lung. J Pain Symptom Manage2006; 32(3): 200-202.
19.
Yano S., Kanematsu T., Miki T., Aono Y., Azuma M., Yamamoto A., et al. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘‘Iressa’’). Cancer Sci2003; 94(5): 453-458.
20.
Milton DT, Kris MG, Gomez JE, and Feinstein MBPrompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). Support Care Cancer2005; 13(1): 70-72.
21.
Venturelli J., Tein I., and Hollenberg R.Increased intracranial pressure associated with N-acetylcysteine inhalation therapy . Crit Care Med1984; 12(10): 926-927.
22.
Ventura P., Panini R., Abbati G., Marchetti G., and Salvioli G.Urinary and plasma homocysteine and cysteine levels during prolonged oral N-acetylcysteine therapy. Pharmacology2003 ; 68(2): 105-114.
23.
Scholze A., Rinder C., Beige J., Riezler R., Zidek W., and Tepel M.Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure . Circulation2004; 109(3): 369-374.
24.
Yilmaz H., Sahin S., Sayar N., Tangurek B., Yilmaz M., Nurkalem Z., et al. Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease. Acta Cardiol2007; 62(6): 579-585.
25.
Roes EM, Raijmakers MTM, Peters WHM, and Steegers EAP.Effects of oral N-acetylcysteine on plasma homocysteine and whole blood glutathione levels in healthy, non-pregnant women . Clin Chem Lab Med2002; 40(5): 496-498.
26.
Wiklund O., Fager G., Andersson A., Lundstam U., Masson P., and Hultberg B.N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Atherosclerosis1996 ; 119(1): 99-106.
27.
Dreisin RB, Mostow SRSulfhydryl-mediated depression of ciliary activity: An adverse effect of acetylcysteine . J Lab Clin Med1979; 93(4): 674-678.
